China-based Shanghai Ark Biopharmaceutical Co., Ltd has completed a Series D financing round, following its Series C round in January 2021. The latest round was led by Loyal Valley Capital and included participation from C&D Emerging Industry Equity Investment, Longda Foods, and existing investors such as Oriza Holdings, Qiming Venture Partners, Shanghai Free Trade Zone Equity Investment Fund Management, Lingang New Area Science and Technology Innovation Fund, and Oriental Fortune Capital.
Company Profile
Founded in 2014, Ark Bio focuses on pediatrics and respiratory diseases. Its core product, AK0529, an anti-respiratory syncytial virus (RSV) drug licensed from Roche in 2014, has completed global Phase III trials with positive results. The company’s ADHD treatment Azstarys (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH]), licensed from Switzerland’s Commave Therapeutics SA in a $105.5 million deal in December 2023, received US market approval.
Strategic Partnerships
Ark Bio has collaborations with multinational pharma firms Roche and Genentech, as well as top academic institutions like the Scripps Institute and the Chinese Academy of Sciences’ Institute of Microbiology.-Fineline Info & Tech
